Skip To Main Content
Ellen Nuttall Musson on Muck Rack

Ellen Nuttall Musson

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ellen Nuttall

Contact Ellen Nuttall, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Analysis of the association of lipid-lowering therapy on clonal dynamics in clonal haematopoiesis of indeterminate potential: insights from the English Longitudinal Study of Ageing | Leukemia

|
By Ellen Nuttall Musson, Phoebe Dace
| Nature Verified
Age-related clonal haematopoiesis of indeterminate potential (CHIP) is a well-described pre-malignant phenomenon that increases the risk of haematological malignancy (HM), cardiovascular disease (CVD) and all-cause mortality, with larger clones (variant allele frequency (VAF) > 10%) conferring higher risk of adverse health outcomes [1,2,3].
Open in Who Shared Issue with article?

Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy-a role for early monitoring and intervention | Leukemia

|
By Marc Mansour, Michelle Lockley, Jonathan A. Ledermann, Ellen Nuttall Musson
| Nature Verified
To the Editor: Poly ADP-ribose polymerase inhibitors (PARPi) are widely used as maintenance treatment for ovarian cancer (OC) after response to platinum chemotherapy in the first-line setting and recurrent disease. Their use has significantly improved outcomes, particularly in patients with BRCA mutations [1] in whom first-line PARPi maintenance therapy increases progression-free survival from 13.8 to 56.0 months (HR:0.33; 95% CI:0.25–0.43).
Open in Who Shared Issue with article?
See all 2 articles